21 May 2013
Keywords: cangene, hep, trial, disappoints, canada, stopped, phase
Article | 16 July 2001
Canada's Cangene has stopped a Phase II pilot trial of itsanti-hepatitis C hyperimmune antibody product in liver transplant
recipients after ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 August 2001
20 May 2013
© 2013 thepharmaletter.com